NICE still down on overall survival benefit of Roche's Herceptin and GSK's Tyverb following appeal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, is still not convinced that either GSK's Tyverb (lapatinib) or Roche's Herceptin (trastuzumab) offer substantial enough overall survival benefit to be recommended as a first-line treatment for some breast cancer patients whose cancer overexpresses HER2. Today's new appraisal consultation document comes after NICE had to rethink previous final draft recommendations in the wake of an appeal from Roche.